DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
semaglutide (Ozempic) to tirzepatide (Zepbound). Dose mapping, washout, expected side effects, and the editorial verdict.
Non-diabetic patients on Ozempic for off-label weight loss who want both the formulary clarity of an on-label weight-loss drug and the efficacy edge of tirzepatide. Combines the rationale of Wegovy switch + Zepbound switch.
No washout. Stop Ozempic, start Zepbound 2.5 mg next injection day. Plan 16-20 weeks to reach maintenance dose.
For weight-loss-focused patients who never had a diabetes diagnosis, Ozempic-to-Zepbound is the logical 2026 destination.
GI side effects reset because you are restarting titration and switching mechanism (GLP-1 to GIP+GLP-1). Sulfur taste and burping are tirzepatide-specific complaints.
Zepbound requires BMI ≥ 30 or ≥ 27 with comorbidity for PA. Off-label Ozempic users without a T2D diagnosis are exactly the population Zepbound was designed for. LillyDirect cash-pay vials are the cheapest direct-pay route in the category.
LillyDirect Zepbound vials ($349-499/mo) cheaper than retail Ozempic without insurance ($900+).
T2D patients with insurance-covered Ozempic should not switch. The administrative friction is significant and Mounjaro is the on-label alternative for diabetes.
Editorial summary, not medical advice. Drug switches should be coordinated with your prescriber. Dose conversions reflect typical practice; your prescriber may adjust based on tolerance, comorbidities, or interactions.